vs
Side-by-side financial comparison of Albemarle Corporation (ALB) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.4B, roughly 1.7× Albemarle Corporation). Zoetis runs the higher net margin — 25.3% vs -29.0%, a 54.3% gap on every dollar of revenue. On growth, Albemarle Corporation posted the faster year-over-year revenue change (15.9% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $233.1M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs 2.4%).
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Lithium, Bromine, and Catalysts. The Lithium segment offers lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and lithium specialties; and reagents, such as butyllithium and lithium aluminum hydride for use in lithium batteries for consumer electronics and electric vehicles, high performance greases, thermoplastic elastomers...
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
ALB vs ZTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $2.4B |
| Net Profit | $-414.2M | $603.0M |
| Gross Margin | 13.9% | 70.2% |
| Operating Margin | -15.2% | 31.9% |
| Net Margin | -29.0% | 25.3% |
| Revenue YoY | 15.9% | 3.0% |
| Net Profit YoY | -650.1% | 3.8% |
| EPS (diluted) | $-3.88 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.4B | $2.4B | ||
| Q3 25 | $1.3B | $2.4B | ||
| Q2 25 | $1.3B | $2.5B | ||
| Q1 25 | $1.1B | $2.2B | ||
| Q4 24 | $1.2B | $2.3B | ||
| Q3 24 | $1.4B | $2.4B | ||
| Q2 24 | $1.4B | $2.4B | ||
| Q1 24 | $1.4B | $2.2B |
| Q4 25 | $-414.2M | $603.0M | ||
| Q3 25 | $-160.7M | $721.0M | ||
| Q2 25 | $22.9M | $718.0M | ||
| Q1 25 | $41.3M | $631.0M | ||
| Q4 24 | $75.3M | $581.0M | ||
| Q3 24 | $-1.1B | $682.0M | ||
| Q2 24 | $-188.2M | $624.0M | ||
| Q1 24 | $2.4M | $599.0M |
| Q4 25 | 13.9% | 70.2% | ||
| Q3 25 | 9.0% | 71.5% | ||
| Q2 25 | 14.8% | 73.6% | ||
| Q1 25 | 14.5% | 72.0% | ||
| Q4 24 | 11.2% | 69.5% | ||
| Q3 24 | -7.7% | 70.6% | ||
| Q2 24 | -0.7% | 71.7% | ||
| Q1 24 | 2.9% | 70.6% |
| Q4 25 | -15.2% | 31.9% | ||
| Q3 25 | -16.6% | 37.0% | ||
| Q2 25 | 3.6% | 36.7% | ||
| Q1 25 | 1.8% | 36.5% | ||
| Q4 24 | 0.4% | 31.6% | ||
| Q3 24 | -81.9% | 36.6% | ||
| Q2 24 | -34.4% | 33.0% | ||
| Q1 24 | -13.2% | 34.1% |
| Q4 25 | -29.0% | 25.3% | ||
| Q3 25 | -12.3% | 30.0% | ||
| Q2 25 | 1.7% | 29.2% | ||
| Q1 25 | 3.8% | 28.4% | ||
| Q4 24 | 6.1% | 25.1% | ||
| Q3 24 | -78.9% | 28.6% | ||
| Q2 24 | -13.2% | 26.4% | ||
| Q1 24 | 0.2% | 27.4% |
| Q4 25 | $-3.88 | $1.37 | ||
| Q3 25 | $-1.72 | $1.63 | ||
| Q2 25 | $-0.16 | $1.61 | ||
| Q1 25 | $0.00 | $1.41 | ||
| Q4 24 | $0.29 | $1.29 | ||
| Q3 24 | $-9.45 | $1.50 | ||
| Q2 24 | $-1.96 | $1.37 | ||
| Q1 24 | $-0.08 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | $3.2B | — |
| Stockholders' EquityBook value | $9.5B | $3.3B |
| Total Assets | $16.4B | $15.5B |
| Debt / EquityLower = less leverage | 0.33× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $1.9B | $2.1B | ||
| Q2 25 | $1.8B | $1.4B | ||
| Q1 25 | $1.5B | $1.7B | ||
| Q4 24 | $1.2B | $2.0B | ||
| Q3 24 | $1.7B | $1.7B | ||
| Q2 24 | $1.8B | $1.6B | ||
| Q1 24 | $2.1B | $2.0B |
| Q4 25 | $3.2B | — | ||
| Q3 25 | $3.6B | — | ||
| Q2 25 | $3.6B | — | ||
| Q1 25 | $3.5B | — | ||
| Q4 24 | $3.5B | — | ||
| Q3 24 | $3.6B | — | ||
| Q2 24 | $3.5B | — | ||
| Q1 24 | $3.5B | — |
| Q4 25 | $9.5B | $3.3B | ||
| Q3 25 | $10.0B | $5.4B | ||
| Q2 25 | $10.2B | $5.0B | ||
| Q1 25 | $10.0B | $4.7B | ||
| Q4 24 | $10.0B | $4.8B | ||
| Q3 24 | $10.2B | $5.2B | ||
| Q2 24 | $11.2B | $5.0B | ||
| Q1 24 | $11.5B | $5.1B |
| Q4 25 | $16.4B | $15.5B | ||
| Q3 25 | $17.1B | $15.2B | ||
| Q2 25 | $17.3B | $14.5B | ||
| Q1 25 | $17.0B | $14.1B | ||
| Q4 24 | $16.6B | $14.2B | ||
| Q3 24 | $17.5B | $14.4B | ||
| Q2 24 | $18.4B | $14.2B | ||
| Q1 24 | $19.0B | $14.3B |
| Q4 25 | 0.33× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 0.35× | — | ||
| Q4 24 | 0.35× | — | ||
| Q3 24 | 0.35× | — | ||
| Q2 24 | 0.31× | — | ||
| Q1 24 | 0.31× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $388.5M | $893.0M |
| Free Cash FlowOCF − Capex | $233.1M | $732.0M |
| FCF MarginFCF / Revenue | 16.3% | 30.7% |
| Capex IntensityCapex / Revenue | 10.9% | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $692.5M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.5M | $893.0M | ||
| Q3 25 | $355.6M | $938.0M | ||
| Q2 25 | $-7.2M | $486.0M | ||
| Q1 25 | $545.4M | $587.0M | ||
| Q4 24 | $674.0K | $905.0M | ||
| Q3 24 | $240.5M | $951.0M | ||
| Q2 24 | $362.9M | $502.0M | ||
| Q1 24 | $98.0M | $595.0M |
| Q4 25 | $233.1M | $732.0M | ||
| Q3 25 | $223.4M | $805.0M | ||
| Q2 25 | $-126.8M | $308.0M | ||
| Q1 25 | $362.8M | $438.0M | ||
| Q4 24 | $-355.1M | $689.0M | ||
| Q3 24 | $-62.6M | $784.0M | ||
| Q2 24 | $-84.7M | $370.0M | ||
| Q1 24 | $-481.4M | $455.0M |
| Q4 25 | 16.3% | 30.7% | ||
| Q3 25 | 17.1% | 33.5% | ||
| Q2 25 | -9.5% | 12.5% | ||
| Q1 25 | 33.7% | 19.7% | ||
| Q4 24 | -28.8% | 29.7% | ||
| Q3 24 | -4.6% | 32.8% | ||
| Q2 24 | -5.9% | 15.7% | ||
| Q1 24 | -35.4% | 20.8% |
| Q4 25 | 10.9% | 6.7% | ||
| Q3 25 | 10.1% | 5.5% | ||
| Q2 25 | 9.0% | 7.2% | ||
| Q1 25 | 17.0% | 6.7% | ||
| Q4 24 | 28.9% | 9.3% | ||
| Q3 24 | 22.4% | 7.0% | ||
| Q2 24 | 31.3% | 5.6% | ||
| Q1 24 | 42.6% | 6.4% |
| Q4 25 | — | 1.48× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | -0.31× | 0.68× | ||
| Q1 25 | 13.19× | 0.93× | ||
| Q4 24 | 0.01× | 1.56× | ||
| Q3 24 | — | 1.39× | ||
| Q2 24 | — | 0.80× | ||
| Q1 24 | 40.01× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALB
| Energy Storage | $759.1M | 53% |
| Specialties | $348.9M | 24% |
| Ketjen | $320.1M | 22% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
